Chongqing, China, June 13, 2025 - Porton Pharma Solutions Ltd. (Porton) today announced that its Changshou site, a flagship site for small molecule API manufacturing, has been awarded a gold medal in the latest EcoVadis sustainability rating, ranking in the top 5% of all participating companies. This achievement not only represents a strong endorsement of Porton’s long-term practices in sustainable development, but also highlights its responsibility in the global pharmaceutical industry chain.
As a global leader in sustainability assessment, EcoVadis has provided authoritative rating services for more than 150,000 enterprises. It provides a critical metric for evaluating company's sustainability management system. Porton’s Changshou site scored 79 (out of 100) in the latest assessment, with particularly outstanding performance in Environment and Labor & Human Rights.
As a key participant in the global pharmaceutical value chain, Porton is dedicated to embedding sustainability into its corporate strategy and operations. Porton joined the United Nations Global Compact (UNGC) in 2017, formally pledging to uphold its Ten Principles. In 2024, Porton further expanded its sustainable program portfolio by participating in the Sustainable Markets Initiative (SMI), where it launched a renewable energy procurement project to reduce carbon emissions. This effort was followed by a significant milestone in 2025: Porton's science-based greenhouse gas emissions reductions targets were validated by the Science Based Targets initiative (the SBTi), demonstrating Porton’s determination in sustainable development. Porton also announced its sustainability targets recently, covering energy consumption, water resources, and waste management.
Porton will further advance its sustainability strategy, catalyzing the global pharmaceutical green transition through excellent practice sharing, and expediting the establishment of a resilient green pharmaceutical ecosystem.
